Miranda Gogishvili

Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial

Ahmet Sezer, Mahmut Gümüş, Igor Bondarenko et al. · The Lancet · 2021 · 772 citations

Radiology, Medicine, Bronchial Neoplasm +9

Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer: a randomized, controlled, double-blind phase 3 trial

Miranda Gogishvili, Tamar Melkadze, Tamta Makharadze et al. · Nature Medicine · 2022 · 268 citations · Full text

Cemiplimab Plus Chemotherapy Versus Chemotherapy Alone in Advanced NSCLC: 2-Year Follow-Up From the Phase 3 EMPOWER-Lung 3 Part 2 Trial

Tamta Makharadze, Miranda Gogishvili, Tamar Melkadze et al. · Journal of Thoracic Oncology · 2023 · 85 citations · Full text

First-line cemiplimab monotherapy and continued cemiplimab beyond progression plus chemotherapy for advanced non-small-cell lung cancer with PD-L1 50% or more (EMPOWER-Lung 1): 35-month follow-up from a mutlicentre, open-label, randomised, phase 3 trial

Mustafa Özgüroğlu, Ahmet Sezer, Mahmut Gümüş et al. · The Lancet Oncology · 2023 · 82 citations

First-line Cemiplimab Monotherapy, Empower-lung 1, Medicine +10

LBA52 EMPOWER-Lung 1: Phase III first-line (1L) cemiplimab monotherapy vs platinum-doublet chemotherapy (chemo) in advanced non-small cell lung cancer (NSCLC) with programmed cell death-ligand 1 (PD-L1) ≥50%

Ahmet Sezer, Mahmut Gümüş, Igor Bondarenko et al. · Annals of Oncology · 2020 · 26 citations · Full text

Medicine, Immunology, Tumor Immunity +8